SecBot SecBot
EFFECT ·Filed Oct 13, 2026

SYRA

Syra Health Corp
NEUTRAL
Impact 4/10
Horizondays Processed14d 16h ago SEC9999999995-26-003196
IPO/offering going effective
Actionable Insight • Neutral

Monitor for any subsequent 8-K or 8-K filing announcing pricing or exercise of warrants; if warrants are exercised, dilution overhang materializes. Effectiveness typically precedes pricing by 1-2 days for IPOs, but this is a resale registration, not an IPO.

DirectionNeutral
Confidencehigh
Horizondays
Latest settled — T+5d
SYRA ▼ -2.35% at T+5d
NEUTRAL call -2.35% · α vs SPY -1.20% · entry $0.8500 → $0.8300
Next anchor: T+20d in 14d
Latest observation: T+8 +9.89% FF3 residual α
Entry = T+0 close
Oct 13, 2026
via day close
T+1d
-0.82%
call -0.82% · α +0.26%
$0.8430
settled 13d ago
T+5d
-2.35%
call -2.35% · α -1.20%
$0.8300
settled 7d ago
T+20d
Pending
in 14d
T+60d
Pending
in 2mo

Price Chart

Loading chart...

Executive Summary

Syra Health Corp's S-1 registration statement (File No. 333-281583) became effective on October 9, 2026, covering the resale of 3,171,100 shares of Class A common stock issuable upon exercise of Series B warrants at $0.64 per share. The effectiveness allows selling stockholders to begin resales immediately, creating potential dilution overhang, though the company receives no proceeds only if warrants are exercised for cash.

Key Facts

  • Effectiveness date: October 9, 2026
  • Registration covers 3,171,100 shares of Class A common stock
  • Shares issuable upon exercise of Series B warrants at $0.64 per share
  • Company will not receive proceeds from resale; could receive ~$2.03 million if all warrants exercised
  • S-1 filed 28 days prior; effectiveness now live
  • Auditor expressed substantial doubt about going concern; company swung to profitability in H1 2026

Financial Impact

Potential proceeds to company of ~$2.03 million if all Series B warrants exercised; no proceeds from resale; resale registration creates dilution risk

dilutiondebtcashRunway

Risk Factors

  • Potential dilution from resale of 3.17M shares overhang
  • Substantial doubt about going concern; auditor expressed doubt
  • No proceeds from resale registration

Investment Themes

Services

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-003196
Document: 9999999995-26-003196-index.html9999999995-26-003196
Document: 9999999995-26-003196.txt9999999995-26-003196
6 reports for SYRA
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for SYRA — sortable, filterable
TypeNow
Oct 13, 2026
14d ago
EFFECT
NEUTRAL ★ 4/10
$0.8500 $0.8300▼ −2.35%▼ −1.20%$0.8600 (+1.18%)
Sep 14, 2026
6w ago
S-1
NEUTRAL ★ 4/10
$0.9400 $0.9600▲ +2.13%▲ +1.31%$0.8600 (−8.51%)
Aug 11, 2026
11w ago
8-K
BULLISH ★ 6/10
$0.6650 $0.7800▲ +17.29%▲ +17.70%$0.8600 (+29.32%)
Jun 1, 2026
21w ago
DEFA14A
NEUTRAL ★ 2/10
$0.5100 $0.4900▼ −3.92%▼ −0.96%$0.8600 (+68.63%)
May 7, 2026
24w ago
8-K
BULLISH ★ 7/10
$0.5000 $0.4390▼ −12.20%▼ −13.70%$0.8600 (+72.00%)
Apr 24, 2026
26w ago
10-K/A
NEUTRAL ★ 2/10
$0.4180 $0.4100▼ −1.91%▼ −2.31%$0.8600 (+105.74%)
Showing 6 of 6

US Market Status

Market Closed — Opens Wed (16h 31m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 13, 2026